مصطلحات الفهرس: drug safety, drug tolerability, dyspnea/si [Side Effect], febrile neutropenia/si [Side Effect], fever/si [Side Effect], human, infection/si [Side Effect], infestation/si [Side Effect], infusion related reaction/dt [Drug Therapy], infusion related reaction/si [Side Effect], monotherapy, nausea/si [Side Effect], neutropenia/si [Side Effect], pharmacodynamic parameters, pharmacokinetic parameters, pharmacological parameters, phase 3 clinical trial (topic), pneumonia/si [Side Effect], priority journal, pruritus/si [Side Effect], rigor/si [Side Effect], tachycardia/si [Side Effect], thrombocytopenia/si [Side Effect], tumor lysis syndrome/si [Side Effect], acalabrutinib/cb [Drug Combination], acalabrutinib/dt [Drug Therapy], bendamustine/dt [Drug Therapy], chlorambucil/ae [Adverse Drug Reaction], chlorambucil/cb [Drug Combination], chlorambucil/dt [Drug Therapy], clarithromycin/it [Drug Interaction], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], fludarabine/cb [Drug Combination], fludarabine/cm [Drug Comparison], fludarabine/dt [Drug Therapy], hydrocortisone/dt [Drug Therapy], ibrutinib/cb [Drug Combination], ibrutinib/cm [Drug Comparison], ibrutinib/dt [Drug Therapy], obinutuzumab/cb [Drug Combination], obinutuzumab/dt [Drug Therapy], posaconazole/it [Drug Interaction], ritonavir/it [Drug Interaction], rituximab/ae [Adverse Drug Reaction], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], venetoclax/ae [Adverse Drug Reaction], venetoclax/cb [Drug Combination], venetoclax/cm [Drug Comparison], venetoclax/it [Drug Interaction], venetoclax/dt [Drug Therapy], obinutuzumab/ae [Adverse Drug Reaction], abdominal pain/si [Side Effect], allogeneic hematopoietic stem cell transplantation, anemia/si [Side Effect], article, backache/si [Side Effect], cancer chemotherapy, cancer immunotherapy, cancer recurrence, chronic lymphatic leukemia/dt [Drug Therapy], chronic lymphatic leukemia/th [Therapy], diarrhea/si [Side Effect], drug efficacy, drug metabolism, drug potentiation, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27245Test
Future Oncology
Click here for full text options
LibKey Link

مصطلحات الفهرس: drug safety, drug tolerability, dyspnea/si [Side Effect], febrile neutropenia/si [Side Effect], fever/si [Side Effect], human, infection/si [Side Effect], infestation/si [Side Effect], infusion related reaction/dt [Drug Therapy], infusion related reaction/si [Side Effect], monotherapy, nausea/si [Side Effect], neutropenia/si [Side Effect], pharmacodynamic parameters, pharmacokinetic parameters, pharmacological parameters, phase 3 clinical trial (topic), pneumonia/si [Side Effect], priority journal, pruritus/si [Side Effect], rigor/si [Side Effect], tachycardia/si [Side Effect], thrombocytopenia/si [Side Effect], tumor lysis syndrome/si [Side Effect], acalabrutinib/cb [Drug Combination], acalabrutinib/dt [Drug Therapy], bendamustine/dt [Drug Therapy], chlorambucil/ae [Adverse Drug Reaction], chlorambucil/cb [Drug Combination], chlorambucil/dt [Drug Therapy], clarithromycin/it [Drug Interaction], cyclophosphamide/cb [Drug Combination], cyclophosphamide/cm [Drug Comparison], cyclophosphamide/dt [Drug Therapy], fludarabine/cb [Drug Combination], fludarabine/cm [Drug Comparison], fludarabine/dt [Drug Therapy], hydrocortisone/dt [Drug Therapy], ibrutinib/cb [Drug Combination], ibrutinib/cm [Drug Comparison], ibrutinib/dt [Drug Therapy], obinutuzumab/cb [Drug Combination], obinutuzumab/dt [Drug Therapy], posaconazole/it [Drug Interaction], ritonavir/it [Drug Interaction], rituximab/ae [Adverse Drug Reaction], rituximab/cb [Drug Combination], rituximab/cm [Drug Comparison], rituximab/dt [Drug Therapy], venetoclax/ae [Adverse Drug Reaction], venetoclax/cb [Drug Combination], venetoclax/cm [Drug Comparison], venetoclax/it [Drug Interaction], venetoclax/dt [Drug Therapy], obinutuzumab/ae [Adverse Drug Reaction], abdominal pain/si [Side Effect], allogeneic hematopoietic stem cell transplantation, anemia/si [Side Effect], article, backache/si [Side Effect], cancer chemotherapy, cancer immunotherapy, cancer recurrence, chronic lymphatic leukemia/dt [Drug Therapy], chronic lymphatic leukemia/th [Therapy], diarrhea/si [Side Effect], drug efficacy, drug metabolism, drug potentiation, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27245Test
Future Oncology
LibKey Link

مصطلحات الفهرس: encorafenib/dt [Drug Therapy], erlotinib/dt [Drug Therapy], fluoropyrimidine/dt [Drug Therapy], fluorouracil/ae [Adverse Drug Reaction], fluorouracil/dt [Drug Therapy], folinic acid/ae [Adverse Drug Reaction], folinic acid/dt [Drug Therapy], gimeracil plus oteracil potassium plus tegafur/dt [Drug Therapy], irinotecan/ae [Adverse Drug Reaction], irinotecan/dt [Drug Therapy], mitomycin/dt [Drug Therapy], oxaliplatin/ae [Adverse Drug Reaction], oxaliplatin/dt [Drug Therapy], panitumumab/dt [Drug Therapy], ramucirumab/dt [Drug Therapy], tipiracil plus trifluridine/ae [Adverse Drug Reaction], tipiracil plus trifluridine/dt [Drug Therapy], trametinib/dt [Drug Therapy], BRAF gene, HER2 gene, KRAS gene, NTRK gene, mrtx 849, vemurafenib/dt [Drug Therapy], cancer chemotherapy, diarrhea/si [Side Effect], evidence based medicine, febrile neutropenia/si [Side Effect], gene, gene amplification, gene expression, gene mutation, human, medical expert, medical specialist, metastatic colorectal cancer/dt [Drug Therapy], microbiome, mismatch repair, neutropenia/si [Side Effect], overall survival, review, signal transduction, aflibercept/dt [Drug Therapy], bevacizumab/dt [Drug Therapy], capecitabine/dt [Drug Therapy], cetuximab/dt [Drug Therapy], circulating tumor DNA/ec [Endogenous Compound], dabrafenib/dt [Drug Therapy], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29281Test
Expert Review of Anticancer Therapy
Click here for full text options
LibKey Link

مصطلحات الفهرس: infusion related reaction/si [Side Effect], intention to treat analysis, leukocyte count, leukopenia/si [Side Effect], longitudinal study, lymphocytopenia/si [Side Effect], major clinical study, male, multicenter study, multiple cycle treatment, nausea/si [Side Effect], neutropenia/si [Side Effect], neutrophil count, open study, overall survival, platelet count, pneumonia/si [Side Effect], priority journal, progression free survival, randomized controlled trial, sepsis/si [Side Effect], septic shock/si [Side Effect], side effect/si [Side Effect], thrombocytopenia/si [Side Effect], treatment duration, treatment outcome, treatment response, treatment withdrawal, tumor lysis syndrome/si [Side Effect], vertigo/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], aspartate aminotransferase/ec [Endogenous Compound], chlorambucil/ae [Adverse Drug Reaction], chlorambucil/ct [Clinical Trial], chlorambucil/cb [Drug Combination], chlorambucil/cm [Drug Comparison], chlorambucil/dt [Drug Therapy], chlorambucil/po [Oral Drug Administration], liver enzyme/ec [Endogenous Compound], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/ct [Clinical Trial], obinutuzumab/cb [Drug Combination], obinutuzumab/cm [Drug Comparison], obinutuzumab/dt [Drug Therapy], obinutuzumab/iv [Intravenous Drug Administration], venetoclax/ae [Adverse Drug Reaction], venetoclax/ct [Clinical Trial], venetoclax/cb [Drug Combination], venetoclax/cm [Drug Comparison], venetoclax/dt [Drug Therapy], venetoclax/po [Oral Drug Administration], life expectancy, acute heart infarction/si [Side Effect], adult, aged, alanine aminotransferase blood level, anemia/si [Side Effect], article, aspartate aminotransferase blood level, asthenia/si [Side Effect], atrial fibrillation/si [Side Effect], basal cell carcinoma/si [Side Effect], chronic lymphatic leukemia/dt [Drug Therapy], clinical effectiveness, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], creatinine clearance, cytokine release syndrome/si [Side Effect], diarrhea/si [Side Effect], drug safety, drug tolerability, dyspnea/si [Side Effect], exploratory research, faintness/si [Side Effect], fatigue/si [Side Effect], febrile neutropenia/si [Side Effect], female, fever/si [Side Effect], follow up, geographic distribution, granulocytopenia/si [Side Effect], headache/si [Side Effect], heart failure/si [Side Effect], heart infarction/si [Side Effect], human, hyperglycemia/si [Side Effect], hypertension/si [Side Effect], hyperuricemia/si [Side Effect], hypotension/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29065Test
The Lancet Oncology
Click here for full text options
LibKey Link

مصطلحات الفهرس: progression free survival, randomized controlled trial, thrombocytopenia/si [Side Effect], thromboembolism/si [Side Effect], treatment response, vomiting/si [Side Effect], carboplatin/ae [Adverse Drug Reaction], carboplatin/ct [Clinical Trial], carboplatin/cb [Drug Combination], carboplatin/cm [Drug Comparison], carboplatin/dt [Drug Therapy], carboplatin/tm [Unexpected Outcome of Drug Treatment], cisplatin/ae [Adverse Drug Reaction], cisplatin/ct [Clinical Trial], cisplatin/cb [Drug Combination], cisplatin/cm [Drug Comparison], cisplatin/dt [Drug Therapy], cisplatin/iv [Intravenous Drug Administration], cisplatin/tm [Unexpected Outcome of Drug Treatment], fluorouracil/ae [Adverse Drug Reaction], fluorouracil/ct [Clinical Trial], fluorouracil/cb [Drug Combination], fluorouracil/cm [Drug Comparison], fluorouracil/dt [Drug Therapy], fluorouracil/tm [Unexpected Outcome of Drug Treatment], paclitaxel/ae [Adverse Drug Reaction], paclitaxel/ct [Clinical Trial], paclitaxel/cm [Drug Comparison], paclitaxel/dt [Drug Therapy], paclitaxel/tm [Unexpected Outcome of Drug Treatment], paclitaxel/cb [Drug Combination], adult, advanced cancer/dt [Drug Therapy], aged, anemia/si [Side Effect], anus cancer/dt [Drug Therapy], article, cancer combination chemotherapy, cancer patient, cancer survival, controlled study, diarrhea/si [Side Effect], drug dose reduction, fatigue/si [Side Effect], febrile neutropenia/si [Side Effect], female, follow up, hearing impairment/si [Side Effect], heart arrhythmia/si [Side Effect], human, infection/si [Side Effect], major clinical study, male, mucosa inflammation/si [Side Effect], multicenter study, multiple cycle treatment, nausea/si [Side Effect], neuropathy/si [Side Effect], neutropenia/si [Side Effect], open study, overall response rate, overall survival, phase 2 clinical trial, priority journal, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28962Test
Journal of Clinical Oncology
LibKey Link

مصطلحات الفهرس: encorafenib/dt [Drug Therapy], erlotinib/dt [Drug Therapy], fluoropyrimidine/dt [Drug Therapy], fluorouracil/ae [Adverse Drug Reaction], fluorouracil/dt [Drug Therapy], folinic acid/ae [Adverse Drug Reaction], folinic acid/dt [Drug Therapy], gimeracil plus oteracil potassium plus tegafur/dt [Drug Therapy], irinotecan/ae [Adverse Drug Reaction], irinotecan/dt [Drug Therapy], mitomycin/dt [Drug Therapy], oxaliplatin/ae [Adverse Drug Reaction], oxaliplatin/dt [Drug Therapy], panitumumab/dt [Drug Therapy], ramucirumab/dt [Drug Therapy], tipiracil plus trifluridine/ae [Adverse Drug Reaction], tipiracil plus trifluridine/dt [Drug Therapy], trametinib/dt [Drug Therapy], BRAF gene, HER2 gene, KRAS gene, NTRK gene, mrtx 849, vemurafenib/dt [Drug Therapy], cancer chemotherapy, diarrhea/si [Side Effect], evidence based medicine, febrile neutropenia/si [Side Effect], gene, gene amplification, gene expression, gene mutation, human, medical expert, medical specialist, metastatic colorectal cancer/dt [Drug Therapy], microbiome, mismatch repair, neutropenia/si [Side Effect], overall survival, review, signal transduction, aflibercept/dt [Drug Therapy], bevacizumab/dt [Drug Therapy], capecitabine/dt [Drug Therapy], cetuximab/dt [Drug Therapy], circulating tumor DNA/ec [Endogenous Compound], dabrafenib/dt [Drug Therapy], Review

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29281Test
Expert Review of Anticancer Therapy
LibKey Link

مصطلحات الفهرس: infusion related reaction/si [Side Effect], intention to treat analysis, leukocyte count, leukopenia/si [Side Effect], longitudinal study, lymphocytopenia/si [Side Effect], major clinical study, male, multicenter study, multiple cycle treatment, nausea/si [Side Effect], neutropenia/si [Side Effect], neutrophil count, open study, overall survival, platelet count, pneumonia/si [Side Effect], priority journal, progression free survival, randomized controlled trial, sepsis/si [Side Effect], septic shock/si [Side Effect], side effect/si [Side Effect], thrombocytopenia/si [Side Effect], treatment duration, treatment outcome, treatment response, treatment withdrawal, tumor lysis syndrome/si [Side Effect], vertigo/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], aspartate aminotransferase/ec [Endogenous Compound], chlorambucil/ae [Adverse Drug Reaction], chlorambucil/ct [Clinical Trial], chlorambucil/cb [Drug Combination], chlorambucil/cm [Drug Comparison], chlorambucil/dt [Drug Therapy], chlorambucil/po [Oral Drug Administration], liver enzyme/ec [Endogenous Compound], obinutuzumab/ae [Adverse Drug Reaction], obinutuzumab/ct [Clinical Trial], obinutuzumab/cb [Drug Combination], obinutuzumab/cm [Drug Comparison], obinutuzumab/dt [Drug Therapy], obinutuzumab/iv [Intravenous Drug Administration], venetoclax/ae [Adverse Drug Reaction], venetoclax/ct [Clinical Trial], venetoclax/cb [Drug Combination], venetoclax/cm [Drug Comparison], venetoclax/dt [Drug Therapy], venetoclax/po [Oral Drug Administration], life expectancy, acute heart infarction/si [Side Effect], adult, aged, alanine aminotransferase blood level, anemia/si [Side Effect], article, aspartate aminotransferase blood level, asthenia/si [Side Effect], atrial fibrillation/si [Side Effect], basal cell carcinoma/si [Side Effect], chronic lymphatic leukemia/dt [Drug Therapy], clinical effectiveness, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], creatinine clearance, cytokine release syndrome/si [Side Effect], diarrhea/si [Side Effect], drug safety, drug tolerability, dyspnea/si [Side Effect], exploratory research, faintness/si [Side Effect], fatigue/si [Side Effect], febrile neutropenia/si [Side Effect], female, fever/si [Side Effect], follow up, geographic distribution, granulocytopenia/si [Side Effect], headache/si [Side Effect], heart failure/si [Side Effect], heart infarction/si [Side Effect], human, hyperglycemia/si [Side Effect], hypertension/si [Side Effect], hyperuricemia/si [Side Effect], hypotension/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29065Test
The Lancet Oncology
LibKey Link

مصطلحات الفهرس: herpes zoster/si [Side Effect], human, human cell, hypertension/si [Side Effect], leukemia relapse, limb injury/si [Side Effect], limit of quantitation, liquid chromatography mass spectrometry, lymph node biopsy, lymphadenopathy, lymphocyte count, lymphocytic lymphoma/dt [Drug Therapy], lymphocytosis, major clinical study, male, maximum plasma concentration, maximum tolerated dose, multicenter study, muscle spasm/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], open study, peripheral blood mononuclear cell, peripheral edema/si [Side Effect], petechia/si [Side Effect], pharmacodynamics, pharmacokinetic parameters, phase 1 clinical trial, plasma concentration-time curve, pneumonia/si [Side Effect], priority journal, progression free survival, purpura/si [Side Effect], rash/si [Side Effect], rhinopharyngitis/si [Side Effect], sinusitis/si [Side Effect], squamous cell skin carcinoma/si [Side Effect], subcutaneous hemorrhage/si [Side Effect], therapeutic dose, therapy delay, thrombocytopenia/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], very elderly, X-ray computed tomography, xerostomia/si [Side Effect], acetylsalicylic acid, alemtuzumab, bendamustine, chlorambucil, clopidogrel, cyclophosphamide, doxorubicin, duvelisib, fludarabine, heparin, idelalisib, lenalidomide, low molecular weight heparin, navitoclax, nonsteroid antiinflammatory agent, obinutuzumab, ofatumumab, pentostatin, prednisone, rituximab, thrombin inhibitor, venetoclax, vincristine, zanubrutinib/ae [Adverse Drug Reaction], zanubrutinib/ct [Clinical Trial], zanubrutinib/dt [Drug Therapy], zanubrutinib/to [Drug Toxicity], zanubrutinib/po [Oral Drug Administration], zanubrutinib/pk [Pharmacokinetics], zanubrutinib/pd [Pharmacology], postprocedural contusion/si [Side Effect], drug half life, abdominal pain/si [Side Effect], acute kidney failure/si [Side Effect], adult, aged, anemia/si [Side Effect], area under the curve, arthralgia/si [Side Effect], article, backache/si [Side Effect], basal cell carcinoma/si [Side Effect], cancer patient, cancer survival, cellulitis/si [Side Effect], chronic lymphatic leukemia/dt [Drug Therapy], clinical outcome, cohort analysis, constipation/si [Side Effect], contusion/si [Side Effect], coughing/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation, dizziness/si [Side Effect], drug blood level, drug dose escalation, drug efficacy, drug safety, drug tolerability, fatigue/si [Side Effect], febrile neutropenia/si [Side Effect], female, follow up, headache/si [Side Effect], hematuria/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35986Test
Blood
Click here for full text options
LibKey Link

مصطلحات الفهرس: neutropenia/si [Side Effect], priority journal, retrospective study, sepsis/si [Side Effect], thrombocytopenia/si [Side Effect], thrombosis/si [Side Effect], treatment response, unspecified side effect/si [Side Effect], bortezomib/cb [Drug Combination], bortezomib/dt [Drug Therapy], cisplatin/ae [Adverse Drug Reaction], cisplatin/cb [Drug Combination], cisplatin/dt [Drug Therapy], cisplatin/iv [Intravenous Drug Administration], cyclophosphamide/ae [Adverse Drug Reaction], cyclophosphamide/cb [Drug Combination], cyclophosphamide/dt [Drug Therapy], cyclophosphamide/iv [Intravenous Drug Administration], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], etoposide/ae [Adverse Drug Reaction], etoposide/cb [Drug Combination], etoposide/dt [Drug Therapy], etoposide/iv [Intravenous Drug Administration], granulocyte colony stimulating factor/dt [Drug Therapy], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], thalidomide/cb [Drug Combination], thalidomide/dt [Drug Therapy], tumor lysis syndrome/si [Side Effect], adult, advanced cancer/dt [Drug Therapy], advanced cancer/th [Therapy], aged, anemia/si [Side Effect], article, autologous stem cell transplantation, cancer combination chemotherapy, febrile neutropenia/dt [Drug Therapy], febrile neutropenia/pc [Prevention], febrile neutropenia/si [Side Effect], female, heart disease/si [Side Effect], herpes zoster/si [Side Effect], human, major clinical study, male, multiple cycle treatment, multiple myeloma/dt [Drug Therapy], multiple myeloma/th [Therapy], mycosis/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37228Test
Leukemia and Lymphoma
Click here for full text options
LibKey Link

مصطلحات الفهرس: herpes zoster/si [Side Effect], human, human cell, hypertension/si [Side Effect], leukemia relapse, limb injury/si [Side Effect], limit of quantitation, liquid chromatography mass spectrometry, lymph node biopsy, lymphadenopathy, lymphocyte count, lymphocytic lymphoma/dt [Drug Therapy], lymphocytosis, major clinical study, male, maximum plasma concentration, maximum tolerated dose, multicenter study, muscle spasm/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], open study, peripheral blood mononuclear cell, peripheral edema/si [Side Effect], petechia/si [Side Effect], pharmacodynamics, pharmacokinetic parameters, phase 1 clinical trial, plasma concentration-time curve, pneumonia/si [Side Effect], priority journal, progression free survival, purpura/si [Side Effect], rash/si [Side Effect], rhinopharyngitis/si [Side Effect], sinusitis/si [Side Effect], squamous cell skin carcinoma/si [Side Effect], subcutaneous hemorrhage/si [Side Effect], therapeutic dose, therapy delay, thrombocytopenia/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], very elderly, X-ray computed tomography, xerostomia/si [Side Effect], acetylsalicylic acid, alemtuzumab, bendamustine, chlorambucil, clopidogrel, cyclophosphamide, doxorubicin, duvelisib, fludarabine, heparin, idelalisib, lenalidomide, low molecular weight heparin, navitoclax, nonsteroid antiinflammatory agent, obinutuzumab, ofatumumab, pentostatin, prednisone, rituximab, thrombin inhibitor, venetoclax, vincristine, zanubrutinib/ae [Adverse Drug Reaction], zanubrutinib/ct [Clinical Trial], zanubrutinib/dt [Drug Therapy], zanubrutinib/to [Drug Toxicity], zanubrutinib/po [Oral Drug Administration], zanubrutinib/pk [Pharmacokinetics], zanubrutinib/pd [Pharmacology], postprocedural contusion/si [Side Effect], drug half life, abdominal pain/si [Side Effect], acute kidney failure/si [Side Effect], adult, aged, anemia/si [Side Effect], area under the curve, arthralgia/si [Side Effect], article, backache/si [Side Effect], basal cell carcinoma/si [Side Effect], cancer patient, cancer survival, cellulitis/si [Side Effect], chronic lymphatic leukemia/dt [Drug Therapy], clinical outcome, cohort analysis, constipation/si [Side Effect], contusion/si [Side Effect], coughing/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation, dizziness/si [Side Effect], drug blood level, drug dose escalation, drug efficacy, drug safety, drug tolerability, fatigue/si [Side Effect], febrile neutropenia/si [Side Effect], female, follow up, headache/si [Side Effect], hematuria/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35986Test
Blood
LibKey Link